antagonist; metabolised to active metabolite R-99224 (IC50
= 45 μM) irreversibly binds platelet P2Y12
receptors, inhibiting platelet activation. Antiplatelet and antithrombotic. Orally active and active in vivo
. Note - inactive in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi et al.
The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.
Huber et al.
Nat.Rev.Drug Discov., 2009;8:449